

# Q2 2021 RESULTS



“ We continue to successfully deliver on our Play to Win strategy, and our solid second quarter performance gives us confidence in our growth trajectory for the remainder of the year. ”

**PAUL HUDSON**

CHIEF EXECUTIVE OFFICER, SANOFI

## COMPANY SALES & BUSINESS EPS\*

Q2 2021 COMPANY SALES\*

**€8,744 M**

+12.4% (+6.5%)

Q2 2021 BUSINESS EPS\*

**€1.38**

+16.4% (+7.8%)

\* Growth rates are expressed at constant exchange rates (CER).  
Growth rates in parentheses are expressed on a reported basis.



**€3,087M**

Specialty Care



**€1,022M**

Vaccines

## SALES BY GLOBAL BUSINESS UNIT



**€3,546M**

General Medicines



**€1,089M**

Consumer Healthcare

## SALES BY GEOGRAPHY

US

**€3,195M**

EUROPE

**€2,244M**



REST OF THE WORLD

**€3,305M**

## KEY MILESTONES DRIVING RESEARCH & DEVELOPMENT TRANSFORMATION



Creation of mRNA Center of Excellence with annual investments of € 400 m



Major advancements in emerging oncology pipeline



Addition of cutting-edge technologies through acquisition of Tidal Therapeutics, Kiadis and Kymab

For further information on Q2 2021 results and definitions of financial indicators, please refer to the press release issued on July 29, 2021 at:

<https://www.sanofi.com/en/investors>



Sanofi.com



@Sanofi



Sanofi



@Sanofi

Sanofi.us



@SanofiUS



SanofiUS